Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Rating of “Hold” by Brokerages

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has received a consensus rating of “Hold” from the nine research firms that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, one has given a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $44.2857.

Several equities analysts have weighed in on ZBIO shares. Guggenheim lifted their target price on Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, March 16th. Zacks Research downgraded Zenas BioPharma from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 17th. HC Wainwright reaffirmed a “buy” rating and issued a $44.00 target price on shares of Zenas BioPharma in a research report on Tuesday, March 17th. Wall Street Zen downgraded Zenas BioPharma from a “hold” rating to a “strong sell” rating in a research report on Saturday, March 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Friday, March 27th.

Zenas BioPharma Stock Down 5.2%

Zenas BioPharma stock opened at $18.90 on Friday. Zenas BioPharma has a fifty-two week low of $8.86 and a fifty-two week high of $44.60. The company has a debt-to-equity ratio of 0.32, a quick ratio of 5.61 and a current ratio of 5.61. The firm has a 50 day moving average price of $21.36 and a 200 day moving average price of $26.81. The company has a market capitalization of $1.08 billion, a PE ratio of -2.23 and a beta of -0.61.

Zenas BioPharma (NASDAQ:ZBIO) last posted its earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.01. During the same quarter last year, the company posted ($0.80) earnings per share. Research analysts expect that Zenas BioPharma will post -4.97 earnings per share for the current year.

Insiders Place Their Bets

In other Zenas BioPharma news, Director Hongbo Lu purchased 3,768 shares of the company’s stock in a transaction on Tuesday, March 31st. The stock was acquired at an average price of $18.63 per share, for a total transaction of $70,197.84. Following the completion of the purchase, the director directly owned 426,736 shares in the company, valued at approximately $7,950,091.68. The trade was a 0.89% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Leon O. Moulder, Jr. acquired 35,000 shares of the stock in a transaction dated Wednesday, April 29th. The shares were bought at an average cost of $17.62 per share, with a total value of $616,700.00. Following the completion of the transaction, the chief executive officer owned 1,786,039 shares of the company’s stock, valued at approximately $31,470,007.18. This represents a 2.00% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired a total of 213,768 shares of company stock worth $4,137,398 over the last 90 days. Corporate insiders own 22.00% of the company’s stock.

Hedge Funds Weigh In On Zenas BioPharma

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quarry LP grew its position in shares of Zenas BioPharma by 34.5% during the third quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after buying an additional 291 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Zenas BioPharma by 17.5% during the first quarter. Bank of New York Mellon Corp now owns 60,864 shares of the company’s stock worth $1,190,000 after buying an additional 9,062 shares in the last quarter. SEB Asset Management AB acquired a new position in shares of Zenas BioPharma during the first quarter worth $3,203,000. Walleye Capital LLC acquired a new position in shares of Zenas BioPharma during the first quarter worth $2,448,000. Finally, Jennison Associates LLC acquired a new position in shares of Zenas BioPharma during the first quarter worth $4,888,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.